OncoMatch/Clinical Trials/NCT07076121
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Is NCT07076121 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including BMS-986504 and Gemcitabine for pancreatic ductal adenocarcinoma.
Treatment: BMS-986504 · Gemcitabine · Nab-paclitaxel — The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in participants with untreated metastatic Pancreatic Ductal Adenocarcinoma (PDAC) with homozygous methylthioadenosine phosphorylase (MTAP) deletion.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: MTAP homozygous deletion
Evidence of homozygous methylthioadenosine phosphorylase (MTAP) deletion detected in tumor tissue
Required: MTAP loss
Evidence of...MTAP loss detected in tumor tissue
Disease stage
Metastatic disease required
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Local Institution - 0142 · Phoenix, Arizona
- Local Institution - 0365 · Tucson, Arizona
- Highlands Oncology Group · Springdale, Arkansas
- Scripps Green Hospital · La Jolla, California
- Local Institution - 0157 · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify